Abstract:Objective: To compare the differences in the clinicopathological and molecular biological features between the breast cancer patients with estrogen receptor (ER) + /progesterone receptor (PR) + or ER + /PR - tumors. Methods: The clinicopathological data of 3124 female breast cancer patients with known ER/PR expression status, 2220 being ER + /PR + and 904 being ER + /PR -, and 1484 being ER - /PR -, were analyzed retrospectively. Immunohistochemistry was used to detect the expression of c-erb and cathapsin D in the tumor specimens. Results: The average peak onset age was 50 years in both the ER + /PR + and ER + PR- patients, and the mean age of the ER + /PR + patients was 52.40 years, not significantly different from that of the ER - /PR - patients (52.57 years, P = 0.709). The peak onset age of the ER + patients was 50 years, significantly higher that that of the ER - patients (48 years, P = 0.001), and the mean age of the ER + patients was 52.46 years, significantly higher than that of the ER - patients (51.42 years, P = 0.001). Univariate analysis showed that ER + /PR - tumors tended to be larger. 24.8% of the ER + /PR- patients had 4 or more metastatic lymph nodes, a rate significantly higher than that of the ER + /PR - patients (20.7%, P = 0.004). The tumors of 18% of the ER + /PR - patients were at the grade III, a rate significantly higher than that of the ER + /PR + patients (13.5%, P = 0.008). The strong positivity rate of the ER + /PR + tumors was 23.4%, ignorantly higher than hat of the ER + /PR - tumors (11.2%, P = 0.000). The c-erB-2 positive rate of the ER + /PR + tumors was 19.7%, significantly lower than that of the ER + /PR - tumor group (28.7%, P = 0.000). The cathepsin D positive rate of the ER + /PR - group was 76.9%, significantly higher than that of the ER + /PR- group (71.9%, P = 0.005). Multivariate analysis indicated that positive PR expression was associated with the level of ER (OR = 1.792,95% CI = 1.484-2.164, P = 0.000), cathepsin D(OR = 1.380,95% CI = 1.023 - 1.862,P = 0.035) and c-erbB-2(OR = 0.639,95% CI = 0.463 - 0.883,P = 0.007). Conclusion: ER + /PR + and ER + /PR - tumors may have identical etiology. The mechanism of whether PR is expressed in ER + breast cancer may be caused by different factors, which causing many different aspects. According to these differences, new target of therapy may provide the possibility of improving the response and prognosis for patients with ER + /PR - tumors.

Evaluation of ER-α, ER-β1 and ER-β2 Expression and Correlation with Clinicopathologic Factors in Invasive Luminal Subtype Breast Cancers

The expressing signification of estrogen receptorβ in breast cancer

Expressions of Progesterone Receptor a and B in Breast Invasive Ductal Carcinoma and Their Clinical Significance

Prognostic Factors for Luminal B-like Breast Cancer

The Molecular Subtypes and Clinicopathologic Features in 267 Cases with Invasive Breast Cancer

Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers

Expression of Estrogen Receptor,progesterone Recptor and C-Erbb-2 in Breast Cancer Tissues

Research on the relationship between the subtypes of breast cancer and breast cancer susceptibility expression

[Relationship Between Breast Cancer Molecular Subtypes with Clinicopathological Characteristics and Prognosis].

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Progesterone Receptor Expression as a Prognostic Factor in Luminal B Breast Cancer

Clinical and X-ray characteristics for expressions of different receptors in patients with breast cancer

Association of ERβ Expression with the Clinical Pathologic Indexes and Prognostic Biomarkers of Breast Cancer

Breast Cancer Subtypes and Survival in Chinese Women with Operable Primary Breast Cancer

The expressions of C - erbB - 2, ER , PR in breast cancer and prognostic significance

Analysis of the Clinicopathologic Characteristics and Prognosis of Breast Cancer Patients with ER or PR Single-positive Status

Clinico-pathological features of ER+/PR+ and ER+/PR-breast tumors:a comparative study of 5211 cases

Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes

Expressions of c-erbB-2, ER, PR and their prognostic correlation in premenopausal and postmenopausal patients with breast cancer.

Clinical Significance of Approximated Molecular Subtypes of Invasive Breast Cancer

Research of Ki67 as index for further classification of ER + and/or PR + breast cancer